"Malaria Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
| Descriptor ID |
D017780
|
| MeSH Number(s) |
D20.215.894.582.500
|
| Concept/Terms |
Malaria Vaccines- Malaria Vaccines
- Vaccines, Malaria
- Malarial Vaccines
- Vaccines, Malarial
|
Below are MeSH descriptors whose meaning is more general than "Malaria Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Malaria Vaccines".
This graph shows the total number of publications written about "Malaria Vaccines" by people in this website by year, and whether "Malaria Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Malaria Vaccines" by people in Profiles.
-
Li X, Huang J, Kawamura A, Funakoshi R, Porcelli SA, Tsuji M. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect. Vaccine. 2017 05 31; 35(24):3171-3177.
-
Kumar R, Ray PC, Datta D, Bansal GP, Angov E, Kumar N. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine. 2015 Sep 22; 33(39):5064-71.
-
Li X, Kawamura A, Andrews CD, Miller JL, Wu D, Tsao T, Zhang M, Oren D, Padte NN, Porcelli SA, Wong CH, Kappe SH, Ho DD, Tsuji M. Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect. J Immunol. 2015 Sep 15; 195(6):2710-21.
-
Kumar R, Ledet G, Graves R, Datta D, Robinson S, Bansal GP, Mandal T, Kumar N. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res. 2015 Dec; 32(12):3827-36.
-
Pusic K, Clements D, Kobuch S, Hui G. Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines. PLoS One. 2013; 8(9):e75939.
-
Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu H, Tsang M, Wang A, Hui G. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J. 2013 Mar; 27(3):1153-66.
-
Pusic K, Xu H, Stridiron A, Aguilar Z, Wang A, Hui G. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine. 2011 Nov 08; 29(48):8898-908.
-
Lau OS, Ng DW, Chan WW, Chang SP, Sun SS. Production of the 42-kDa fragment of Plasmodium falciparum merozoite surface protein 1, a leading malaria vaccine antigen, in Arabidopsis thaliana seeds. Plant Biotechnol J. 2010 Dec; 8(9):994-1004.
-
Omosun YO, Adoro S, Anumudu CI, Odaibo A, Holder AA, Nwagwu M, Nwuba RI. Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies. Afr Health Sci. 2010 Jun; 10(2):106-10.
-
Okafor CM, Anumudu CI, Omosun YO, Uthaipibull C, Ayede I, Awobode HO, Odaibo AB, Langhorne J, Holder AA, Nwuba RI, Troye-Blomberg M. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection. Malar J. 2009 Nov 23; 8:263.